Clinical trial
Mendelian Randomization Analysis of Drug Targets: Exploring the Impact of Antihypertensive and Lipid-Lowering Therapies on Inflammatory Cytokines
NCT06622304 is registered in ClinicalTrials.gov with Guangzhou Institute of Respiratory Disease as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Mendelian Randomization Analysis of Drug Targets: Exploring the Impact of Antihypertensive and Lipid-Lowering Therapies on Inflammatory Cytokines
- Lead sponsor
- Guangzhou Institute of Respiratory Disease
- Phase
- Observational
- Overall status
- Completed
- Start date
- April 1, 2024
- Completion date
- September 11, 2024
- Enrollment
- Not reported
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
chronic inflammation, dyslipidemias, hypertension, inflammatory cytokines, inflammatory response